| Original language | English (US) |
|---|---|
| Pages (from-to) | 985-987 |
| Number of pages | 3 |
| Journal | Pharmacotherapy |
| Volume | 37 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 2017 |
Bibliographical note
Funding Information:This evolution from pharmacogenomics to precision medicine has been driven by advancements in our knowledge of disease mechanisms that have improved treatments for complex illnesses. These advances have been supported by a general research-sharing infrastructure provided by the National Institutes of Health (NIH). In 2000, the NIH supported the creation of the Pharmacoge-nomics Knowledge Base (PharmGKB) and the Pharmacogenomics Research Network (PGRN), which currently still serves as a primary resource for pharmacogenomic information. In fact, the partnership between PharmGKB and the PGRN has resulted in the establishment of the Clinical Pharmacogenomics Implementation Consortium (CPIC), which provides clinical practice guidelines for the interpretation of pharmacogenomic results, as it recognized early that guidelines were needed to help clinicians make rational prescribing decisions based on pharmacogenomic information.5 Recently, work has described that one of